bladder cancer

positive negative up down good bad mixed
Biotech

Tyra rolls toward pivotal cancer study even as stock deflates

Tyra reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year.
Nick Paul Taylor Sep 9, 2026 9:30am
Eli Lilly booth at AACR 2026

ASCO: Lilly debuts ‘strong’ data for potential Padcev challenger

May 29, 2026 8:00am
downfall

EnGene cancer sales forecast cut after new data widen gap to J&J

May 8, 2026 9:08am
cancer target detection radiopharma radio

Protara sees 66% bladder cancer response rate at 6 months

Feb 24, 2026 6:50am
Deal terminate tear up end deal scrap

UroGen hands CTLA-4 drug back to Agenus after mulling ph. 1 data

Nov 6, 2025 10:00am
Tecentriq
Favicon Fierce Pharma

Roche touts Tecentriq biomarker win in bladder cancer

Aug 18, 2025 4:17pm